Bristol-Myers Squibb (BMY)
Market Price (12/24/2025): $54.37 | Market Cap: $110.7 BilSector: Health Care | Industry: Pharmaceuticals
Bristol-Myers Squibb (BMY)
Market Price (12/24/2025): $54.37Market Cap: $110.7 BilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 10.0%, Dividend Yield is 4.5%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 5.8%, FCF Yield is 14% | Weak multi-year price returns2Y Excs Rtn is -30%, 3Y Excs Rtn is -95% | Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 1.0% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 24% | Key risks[BMY] key risks include [1] the impending patent expirations for its blockbuster drugs Eliquis, Show more. | |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 35%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 32%, CFO LTM is 17 Bil, FCF LTM is 15 Bil | ||
| Low stock price volatilityVol 12M is 29% | ||
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 10.0%, Dividend Yield is 4.5%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 5.8%, FCF Yield is 14% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 24% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 35%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 32%, CFO LTM is 17 Bil, FCF LTM is 15 Bil |
| Low stock price volatilityVol 12M is 29% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -30%, 3Y Excs Rtn is -95% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 1.0% |
| Key risks[BMY] key risks include [1] the impending patent expirations for its blockbuster drugs Eliquis, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Bristol-Myers Squibb (BMY) experienced significant stock movement due to several key developments. 1. Acquisition of Karuna Therapeutics: The company announced the acquisition of Karuna Therapeutics for approximately $14 billion, bringing KarXT, a potential first-in-class schizophrenia drug, into its neuroscience portfolio. This strategic move is anticipated to enhance future revenue growth and diversify the pipeline.2. Acquisition of RayzeBio: Bristol-Myers Squibb entered into an agreement to acquire RayzeBio for about $4.1 billion, adding a pipeline of radiopharmaceuticals and manufacturing infrastructure for targeted cancer therapies. This acquisition marked a strategic entry into a rapidly growing area of oncology.
Show more
Stock Movement Drivers
Fundamental Drivers
The 22.5% change in BMY stock from 9/23/2025 to 12/23/2025 was primarily driven by a 18.8% change in the company's Net Income Margin (%).| 9232025 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 44.30 | 54.28 | 22.53% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 47704.00 | 48034.00 | 0.69% |
| Net Income Margin (%) | 10.58% | 12.57% | 18.79% |
| P/E Multiple | 17.86 | 18.30 | 2.49% |
| Shares Outstanding (Mil) | 2035.00 | 2036.00 | -0.05% |
| Cumulative Contribution | 22.53% |
Market Drivers
9/23/2025 to 12/23/2025| Return | Correlation | |
|---|---|---|
| BMY | 22.5% | |
| Market (SPY) | 3.7% | 11.4% |
| Sector (XLV) | 13.2% | 54.6% |
Fundamental Drivers
The 18.5% change in BMY stock from 6/24/2025 to 12/23/2025 was primarily driven by a 10.5% change in the company's Net Income Margin (%).| 6242025 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 45.79 | 54.28 | 18.55% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 47636.00 | 48034.00 | 0.84% |
| Net Income Margin (%) | 11.38% | 12.57% | 10.52% |
| P/E Multiple | 17.16 | 18.30 | 6.64% |
| Shares Outstanding (Mil) | 2031.00 | 2036.00 | -0.25% |
| Cumulative Contribution | 18.54% |
Market Drivers
6/24/2025 to 12/23/2025| Return | Correlation | |
|---|---|---|
| BMY | 18.5% | |
| Market (SPY) | 13.7% | 11.1% |
| Sector (XLV) | 16.4% | 61.6% |
Fundamental Drivers
The -1.0% change in BMY stock from 12/23/2024 to 12/23/2025 was primarily driven by a -1.9% change in the company's P/S Multiple.| 12232024 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 54.85 | 54.28 | -1.05% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 47435.00 | 48034.00 | 1.26% |
| P/S Multiple | 2.35 | 2.30 | -1.89% |
| Shares Outstanding (Mil) | 2028.00 | 2036.00 | -0.39% |
| Cumulative Contribution | -1.05% |
Market Drivers
12/23/2024 to 12/23/2025| Return | Correlation | |
|---|---|---|
| BMY | -1.0% | |
| Market (SPY) | 16.7% | 20.7% |
| Sector (XLV) | 13.2% | 64.4% |
Fundamental Drivers
The -15.0% change in BMY stock from 12/24/2022 to 12/23/2025 was primarily driven by a -12.0% change in the company's Net Income Margin (%).| 12242022 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 63.82 | 54.28 | -14.95% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 46738.00 | 48034.00 | 2.77% |
| Net Income Margin (%) | 14.29% | 12.57% | -12.00% |
| P/E Multiple | 20.39 | 18.30 | -10.24% |
| Shares Outstanding (Mil) | 2133.00 | 2036.00 | 4.55% |
| Cumulative Contribution | -15.13% |
Market Drivers
12/24/2023 to 12/23/2025| Return | Correlation | |
|---|---|---|
| BMY | 14.5% | |
| Market (SPY) | 48.4% | 14.2% |
| Sector (XLV) | 18.2% | 50.1% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BMY Return | 0% | 3% | 19% | -26% | 16% | 1% | 7% |
| Peers Return | 12% | 36% | 21% | 2% | 8% | 26% | 156% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 17% | 114% |
Monthly Win Rates [3] | |||||||
| BMY Win Rate | 42% | 42% | 75% | 25% | 67% | 58% | |
| Peers Win Rate | 50% | 62% | 62% | 43% | 47% | 62% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| BMY Max Drawdown | -27% | -12% | -1% | -30% | -20% | -21% | |
| Peers Max Drawdown | -22% | -6% | -11% | -20% | -6% | -13% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: MRK, PFE, JNJ, ABBV, LLY. See BMY Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/23/2025 (YTD)
How Low Can It Go
| Event | BMY | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -40.2% | -25.4% |
| % Gain to Breakeven | 67.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -31.2% | -33.9% |
| % Gain to Breakeven | 45.3% | 51.3% |
| Time to Breakeven | 476 days | 148 days |
| 2018 Correction | ||
| % Loss | -38.0% | -19.8% |
| % Gain to Breakeven | 61.3% | 24.7% |
| Time to Breakeven | 743 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -46.3% | -56.8% |
| % Gain to Breakeven | 86.2% | 131.3% |
| Time to Breakeven | 1,084 days | 1,480 days |
Compare to
In The Past
Bristol-Myers Squibb's stock fell -40.2% during the 2022 Inflation Shock from a high on 12/2/2022. A -40.2% loss requires a 67.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
AI Analysis | Feedback
A major pharmaceutical company, similar to Pfizer or Merck.
A leading biopharmaceutical developer, akin to the pharmaceutical division of Johnson & Johnson or Roche.
AI Analysis | Feedback
- Opdivo (nivolumab): A programmed death-1 (PD-1) blocking antibody used in the treatment of various cancers, including melanoma, lung, and renal cell carcinoma.
- Eliquis (apixaban): An oral anticoagulant prescribed to prevent strokes and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and prevention of deep vein thrombosis and pulmonary embolism.
- Revlimid (lenalidomide): An immunomodulatory drug primarily indicated for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma.
- Yervoy (ipilimumab): A CTLA-4 blocking antibody used as an immunotherapy for advanced melanoma, renal cell carcinoma, and other cancers, often in combination with Opdivo.
- Orencia (abatacept): A selective T-cell costimulation modulator used to treat rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis by inhibiting T-cell activation.
- Sotyktu (deucravacitinib): An oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of moderate-to-severe plaque psoriasis.
AI Analysis | Feedback
Bristol-Myers Squibb (BMY) primarily sells its pharmaceutical products to other companies, specifically major wholesale distributors. These distributors then supply pharmacies, hospitals, and other healthcare providers with Bristol-Myers Squibb's medications.
Based on their 2023 annual report (10-K), the major customer companies that individually accounted for more than 10% of Bristol-Myers Squibb's U.S. gross product sales are:
- AmerisourceBergen Corporation (Symbol: ABC)
- Cardinal Health, Inc. (Symbol: CAH)
- McKesson Corporation (Symbol: MCK)
AI Analysis | Feedback
nullAI Analysis | Feedback
Chris Boerner, Board Chair and Chief Executive Officer
Chris Boerner was appointed Chief Executive Officer in November 2023 and Board Chair in April 2024. His previous roles at Bristol Myers Squibb include Executive Vice President, Chief Operating Officer and CEO-elect, Executive Vice President, Chief Commercialization Officer, head of International Markets, and head of U.S. Commercial Markets. Before joining BMS in 2015, he held leadership positions at Seattle Genetics, Inc. from 2010 to 2015 and marketing leadership roles at Genentech, a member of the Roche Group, from 2002 to 2010, focusing on oncology products and immunology. Earlier in his career, he worked for McKinsey & Company, serving global pharmaceutical and biotechnology clients. He earned a PhD and MA in business administration from the Haas School of Business at the University of California, Berkeley, and a BA in economics and history from Washington University in St. Louis.
David Elkins, Executive Vice President and Chief Financial Officer
David Elkins joined Bristol Myers Squibb in 2019 as a result of the acquisition of Celgene, where he was Executive Vice President and Chief Financial Officer. Prior to Celgene, he served as Chief Financial Officer for Johnson & Johnson's Consumer Products, Medical Device businesses, and Corporate Functions. He also held the position of Executive Vice President and Chief Financial Officer of Becton, Dickinson and Company. His career includes roles of increasing responsibility at AstraZeneca from 1995 to 2008 and he began his finance career at The Boeing Company. He was also a member of the management board of Medimmune Inc. after AstraZeneca's acquisition of the company.
Lynelle B. Hoch, President, Cell Therapy Organization
Lynelle B. Hoch leads Bristol Myers Squibb's cross-functional cell therapy business, overseeing the research, development, manufacturing, and commercialization of the company's marketed and pipeline cell therapies. She has over 25 years of experience at BMS in sales, marketing, and market access, both internationally and in the U.S. Before her current role, she served as the general manager for BMS in the UK and Ireland and successfully led the marketing organization for the immuno-oncology portfolio. She started her career as an engineer intern in manufacturing and holds a BS in geoenvironmental engineering from The Pennsylvania State University.
Karin Shanahan, Executive Vice President, Chief Supply Chain & Operations Officer
Karin Shanahan oversees product development, quality, manufacturing, and supply chain for Bristol Myers Squibb. She began her career at Bristol Myers Squibb in corporate procurement, global supply chain, and global quality, and also led two manufacturing sites in Billerica, MA, and Latina, Italy. After her initial tenure at BMS, she joined Becton-Dickinson as a leader of global operations, followed by Catalent Pharmaceuticals where she led global Biologics operations. In 2013, she became Senior Vice President and Chief Operating Officer of global operations at Teva Pharmaceuticals, leading a network of 25 sites across Europe and the Americas. Most recently, she served as Senior Vice President of Global Biologics & Sterile Operations at Merck. She holds a bachelor's degree in political science and international relations from Rutgers University and a master's degree in jurisprudence (MSJ), pharmaceutical and device law, from Seton Hall Law School.
Cristian Massacesi, MD, Executive Vice President, Chief Medical Officer and Head of Development
Cristian Massacesi, MD, joined Bristol Myers Squibb in August 2025. Prior to this, he served as the Chief Medical Officer of AstraZeneca. His professional experience also includes roles at Pfizer, Alexion, and Novartis.
AI Analysis | Feedback
The primary and most significant risk to Bristol-Myers Squibb (BMY) is the impending patent expirations of its key blockbuster drugs, notably Eliquis, Opdivo, and Revlimid. These drugs constitute a substantial portion of the company's revenue, with Revlimid, Eliquis, and Opdivo collectively making up approximately 58.3% of the company's revenue in the third quarter of 2023. Revlimid has already begun facing generic competition, and Eliquis and Opdivo are expected to lose U.S. patent exclusivity in 2026 and 2028, respectively.
A second key risk is the company's reliance on its research and development (R&D) pipeline and new product launches to offset the significant revenue decline anticipated from these patent expirations. The pharmaceutical industry inherently faces a high rate of failure in drug development, meaning there is a considerable risk that investments in research programs may not generate expected financial returns. While Bristol-Myers Squibb is strategically focusing on new product launches and pipeline development, the success of these initiatives to compensate for the projected revenue shortfall is not guaranteed.
Finally, increasing competition from generics and biosimilars, coupled with ongoing pricing pressures, poses another significant risk. As key drugs lose exclusivity, they face immediate and substantial competition from more affordable alternatives, leading to a drastic reduction in their profit contributions.
AI Analysis | Feedback
- Imminent loss of exclusivity for key revenue drivers, most notably Eliquis (Apixaban). Eliquis, a leading oral anticoagulant and one of Bristol-Myers Squibb's top-selling drugs, faces loss of exclusivity in major markets, including the United States, starting around 2028-2029. This will lead to the entry of generic competitors and is projected to result in a substantial decline in revenue, posing a significant financial challenge that requires substantial new pipeline contributions to offset.
- The rapid expansion and therapeutic scope of GLP-1 agonists. The immense success and growing indications of GLP-1 receptor agonists (e.g., Ozempic/Wegovy from Novo Nordisk, Mounjaro/Zepbound from Eli Lilly) for diabetes, obesity, and cardiovascular benefits are profoundly reshaping the pharmaceutical landscape. While Bristol-Myers Squibb does not currently have a significant presence in this drug class, the substantial shift in healthcare spending, R&D focus, and patient demand towards these highly effective therapies could indirectly impact BMY's ability to compete for market share and investment in other therapeutic areas, or potentially alter treatment paradigms for conditions where BMY has existing products.
- Accelerated drug discovery and development through advanced Artificial Intelligence (AI) and Machine Learning (ML). The increasing integration and demonstrated capabilities of AI/ML platforms by competitors and specialized biotechnology companies are enabling faster identification of novel drug targets, more efficient lead optimization, and accelerated clinical development. Companies leveraging these advanced computational methods could potentially bring new, more effective drugs to market more rapidly and at a lower cost, posing a competitive threat to traditional R&D pipelines and potentially eroding market share if Bristol-Myers Squibb does not adequately adopt and scale similar capabilities.
AI Analysis | Feedback
Addressable Markets for Bristol-Myers Squibb's Main Products:
- Eliquis (apixaban):
- The global market size for Eliquis was estimated at approximately USD 20.70 billion in 2024, with projections to reach USD 18.87 billion by 2033, experiencing a declining compound annual growth rate (CAGR) of -2.2%. Other estimates for the global market vary, including USD 20.15 billion in 2024, projected to grow to USD 31.74 billion by 2034 with a CAGR of 4.65%, and USD 31.04 billion in 2023, projected to reach USD 75.53 billion by 2031 with a CAGR of 9.3%. Another source estimated the global market size at $8 billion in 2025, with a projected market size exceeding $17 billion by 2033 at an estimated 8% CAGR.
- North America held the largest share of the Eliquis market, accounting for 32.56% in 2024, and 34.1% with a revenue of US$ 6.9 billion in 2024. The U.S. market size was USD 4.94 billion in 2024 and is projected to reach approximately USD 7.94 billion by 2034.
- Opdivo (nivolumab):
- The global Opdivo market size is projected to grow from $7,709.49 million in 2024 to $8,335.54 million in 2025, at a CAGR of 8.1%. It is expected to reach $11,281.56 million in 2029, with a CAGR of 7.9%. Another projection indicates the global market size will grow from USD 7.2 billion in 2023 to approximately USD 14.5 billion by 2032, at a CAGR of 7.8%. Worldwide sales were $9.3 billion in 2022 and are forecast to reach $14 billion by 2028.
- North America was the largest region in the Opdivo market in 2024 and is expected to maintain its leading position throughout the forecast period with a CAGR of 6.5%.
- Revlimid (lenalidomide):
- The global Revlimid market size was valued at approximately USD 14 billion in 2023 and is projected to reach around USD 25 billion by 2032, growing at a CAGR of 6.5%. However, other reports indicate a decline, with an estimated global market size of USD 10.80 billion in 2025 and a projected decrease to USD 4.77 billion by 2032, exhibiting a negative CAGR of -11.0%. Another source valued it at $7.943 billion in 2025, projected to decline with a CAGR of -10.5% from 2025 to 2033. Global drug sales stood at USD 6,173 million in 2023.
- North America currently dominates the Revlimid market and is expected to hold a significant 32.3% market share in 2025.
- Orencia (abatacept):
- The global Orencia market size was valued at approximately USD 2.3 billion in 2023 and is projected to reach USD 4.8 billion by 2032, with a CAGR of 8.5%. Other reports show the global market size growing from $3.71 billion in 2024 to $3.92 billion in 2025 (CAGR of 5.9%), and expected to reach $4.98 billion in 2029 (CAGR of 6.1%). Another report indicates a global market size of USD 2.5 billion in 2023, projected to reach around USD 4.3 billion by 2032, reflecting a CAGR of 6.2%. Additionally, the Orencia Abatacept Drug Market size was valued at USD 3.8 billion in 2024 and is projected to reach USD 6.7 billion by 2032, growing at a CAGR of 7.35%.
- North America was the largest region in the Orencia abatacept drug market in 2024 and has the biggest market share.
- Reblozyl (luspatercept):
- Reblozyl's projected total annual global sales are anticipated to reach $3.2 billion by 2029. As of Q3 2025, it is generating annualized sales exceeding $2 billion.
- North America was the largest region in the Reblozyl market in 2024.
- Zeposia (ozanimod):
- The global Zeposia market was valued at USD 450 million in 2023 and is projected to reach USD 1467.83 million by 2032, at a CAGR of 18.4%. Another source states it was USD 296 million in 2023 and is likely to reach USD 1370 million by 2032, expanding at a CAGR of 18.4%. Estimates for 2025 suggest a market size of $500 million, with projections to reach approximately $1.3 billion by 2033, at a CAGR of 15%. Other figures indicate a global market size of US$ 540 million in 2024, forecast to reach US$ 1695 million by 2031 with a CAGR of 18.0%, and a valuation of USD 350.46 million in 2024, expected to reach USD 414.94 million in 2025, growing to USD 2436.25 million by 2033, reflecting a robust CAGR of 18.4%.
- North America is expected to hold a significant market share, holding a major share in 2023, and contributing around 50% of the market.
- Camzyos (mavacamten):
- The addressable market for obstructive hypertrophic cardiomyopathy (oHCM) in the U.S. affects 600,000–700,000 people. Analysts project that achieving 20% penetration of this population could push annual sales above $1 billion. Bristol Myers expects the drug to score $4 billion or more in peak sales (global). The consensus of Wall Street analysts is $2.5 billion in worldwide sales by 2029. Sales of Camzyos were $260 million globally and $214 million in the United States in Q3 2025.
- Sotyktu (deucravacitinib):
- Sotyktu has a global sales forecast of $2.9 billion by 2029 and is set to become a blockbuster for the treatment of plaque psoriasis.
AI Analysis | Feedback
Bristol-Myers Squibb (BMY) anticipates future revenue growth over the next 2-3 years will be driven by several key factors:
- Robust Performance of Key Growth Products: The company's "growth portfolio" is expected to continue delivering strong sales. This portfolio includes established products such as Opdivo, Reblozyl, Camzyos, and Breyanzi, which have demonstrated significant year-over-year revenue increases and have achieved or are nearing multi-billion dollar annual sales run rates.
- Advancements and Launches from a Deep Pipeline: Bristol-Myers Squibb has a robust pipeline with numerous clinical data readouts anticipated in 2025 and 2026, and expects to introduce up to 10 new medicines by 2030. Specific promising new molecular entities mentioned include Milvexian, a next-generation anticoagulant with potential for significant impact, and recently launched products like Cobenfy and Qvantig, which are contributing to growth.
- Strategic Business Development and Partnerships: Strategic acquisitions and collaborations are critical for expanding the company's therapeutic reach and technological capabilities. The acquisition of Orbital Therapeutics, for instance, aims to advance in-vivo CAR-T and RNA platforms, potentially revolutionizing cell therapy and broadening treatment options for autoimmune diseases. Partnerships, such as the global strategic partnership with BioNTech for the co-development of BNT327 in immuno-oncology, also underscore this driver.
- Label Expansions and Increased Market Penetration for Existing Therapies: Expanding the approved indications for current growth drivers will unlock new patient populations and market opportunities. Examples include the European approval for Opdivo in neoadjuvant lung cancer and new approvals for Breyanzi across multiple lymphoma and leukemia indications, as well as priority review for Reblozyl for expanded use in anemia patients.
AI Analysis | Feedback
```htmlShare Repurchases
- In 2023, Bristol-Myers Squibb repurchased approximately $5.2 billion of its common stock, including $4.0 billion through Accelerated Share Repurchase agreements.
- As of December 31, 2023, the total outstanding share repurchase authorization was approximately $5 billion, following an additional $3 billion authorization in December 2023.
- In December 2021, the Board of Directors authorized an additional $15 billion for a multi-year share repurchase program.
Share Issuance
- Bristol-Myers Squibb's net total equity issued/repurchased for 2024 was $0 billion, indicating no net issuance for the year.
- In 2023, the net total equity issued/repurchased was approximately -$5.155 billion, and in 2022, it was approximately -$8.001 billion, reflecting net repurchases rather than issuances.
Outbound Investments
- In 2020, Bristol-Myers Squibb acquired MyoKardia for $13.1 billion, enhancing its cardiovascular disease therapies portfolio.
- In 2024, the company completed several significant acquisitions, including Mirati Therapeutics for $4.8 billion (plus a potential $1 billion in milestone payments), Karuna Therapeutics for $14 billion, and RayzeBio for $4.1 billion, diversifying its oncology and neuroscience pipelines.
- In December 2023, Bristol-Myers Squibb announced a global strategic collaboration agreement with SystImmune, involving an $800 million upfront payment and potential contingent payments up to $7.1 billion.
Capital Expenditures
- Capital expenditures averaged $1.06 billion annually from fiscal years 2020 to 2024, with reported amounts of $753 million in 2020, $973 million in 2021, $1.118 billion in 2022, $1.209 billion in 2023, and $1.248 billion in 2024.
- Expected capital expenditures are approximately $1.4 billion for both 2024 and 2025, primarily focused on expanding cell therapy and other manufacturing capabilities, research and development, and facility-related activities.
- In February 2024, an investment of $400 million was announced for a new Sterile Drug Product facility at its Dublin 15 Cruiserath Campus, set for completion in 2026, to support manufacturing and supply of existing and pipeline medicines.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to BMY. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.0% | 21.0% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -8.8% | -8.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 11.5% | 11.5% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.7% | 2.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 13.8% | 13.8% | -5.1% |
| 07312025 | BMY | Bristol-Myers Squibb | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 27.9% | 27.9% | -0.3% |
| 04302024 | BMY | Bristol-Myers Squibb | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 22.7% | 19.9% | -8.8% |
| 10312023 | BMY | Bristol-Myers Squibb | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -12.7% | 7.4% | -20.4% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Bristol-Myers Squibb
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 155.41 |
| Mkt Cap | 333.4 |
| Rev LTM | 61,215 |
| Op Inc LTM | 18,904 |
| FCF LTM | 14,176 |
| FCF 3Y Avg | 13,642 |
| CFO LTM | 16,843 |
| CFO 3Y Avg | 16,176 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.5% |
| Rev Chg 3Y Avg | 2.0% |
| Rev Chg Q | 5.2% |
| QoQ Delta Rev Chg LTM | 1.3% |
| Op Mgn LTM | 25.4% |
| Op Mgn 3Y Avg | 25.1% |
| QoQ Delta Op Mgn LTM | 1.7% |
| CFO/Rev LTM | 26.4% |
| CFO/Rev 3Y Avg | 27.3% |
| FCF/Rev LTM | 20.3% |
| FCF/Rev 3Y Avg | 21.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 333.4 |
| P/S | 4.7 |
| P/EBIT | 13.6 |
| P/E | 19.0 |
| P/CFO | 17.4 |
| Total Yield | 8.8% |
| Dividend Yield | 3.0% |
| FCF Yield 3Y Avg | 5.5% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 1.0% |
| 3M Rtn | 19.9% |
| 6M Rtn | 29.2% |
| 12M Rtn | 21.2% |
| 3Y Rtn | 15.0% |
| 1M Excs Rtn | -3.6% |
| 3M Excs Rtn | 16.8% |
| 6M Excs Rtn | 16.4% |
| 12M Excs Rtn | 6.0% |
| 3Y Excs Rtn | -62.5% |
Comparison Analyses
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA220073 | ELIQUIS | apixaban | suspension | 4172025 | -1.1% | -9.5% | 14.0% | 14.0% | 14.0% |
| BLA761381 | OPDIVO QVANTIG | nivolumab | injectable | 12272024 | 5.2% | -17.9% | -0.5% | -0.5% | -0.5% |
| BLA761429 | OPDIVO QVANTIG | nivolumab | injectable | 12272024 | 5.2% | -17.9% | -0.5% | -0.5% | -0.5% |
| NDA216158 | COBENFY | trospium chloride | capsule | 9262024 | 17.0% | 20.1% | -6.6% | 15.8% | 15.8% |
| NDA218213 | AUGTYRO | repotrectinib | capsule | 11152023 | -4.1% | -11.6% | 19.2% | -0.2% | 16.9% |
| NDA216340 | KRAZATI | adagrasib | tablet | 12122022 | -15.7% | -16.6% | -33.7% | -21.9% | -20.9% |
| NDA214958 | SOTYKTU | deucravacitinib | tablet | 9092022 | 13.2% | -4.9% | -10.4% | -24.7% | -10.3% |
| NDA214998 | CAMZYOS | mavacamten | capsule | 4282022 | -2.6% | -2.0% | -10.8% | -37.5% | -18.0% |
| BLA761234 | OPDUALAG | nivolumab | solution | 3182022 | 4.6% | 2.2% | -3.5% | -21.1% | -10.2% |
| NDA214120 | ONUREG | azacitidine | tablet | 9012020 | 3.1% | 2.1% | 11.3% | 20.5% | 9.7% |
| ... | |||||||||
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Eliquis | 12,206 | 11,789 | 10,762 | 9,168 | 7,929 |
| Opdivo | 9,009 | 8,249 | 7,523 | 6,992 | 7,204 |
| Revlimid | 6,097 | 9,978 | 12,821 | 12,106 | 1,299 |
| Orencia | 3,601 | 3,464 | 3,306 | 3,157 | 2,977 |
| Pomalyst/Imnovid | 3,441 | 3,497 | 3,332 | 3,070 | 322 |
| Yervoy | 2,238 | 2,131 | 2,026 | 1,682 | 1,489 |
| Sprycel | 1,930 | 2,165 | 2,117 | 2,140 | 2,110 |
| Other Growth products | 1,211 | ||||
| Reblozyl | 1,008 | 717 | 551 | 274 | |
| Abraxane | 1,004 | 811 | 1,181 | 1,247 | 166 |
| Other Legacy products | 962 | ||||
| Opdualag | 627 | 252 | |||
| Abecma | 472 | 388 | 164 | ||
| Zeposia | 434 | 250 | 134 | 12 | |
| Breyanzi | 364 | 182 | 87 | ||
| Camzyos | 231 | 24 | |||
| Sotyktu | 170 | 8 | |||
| Augtyro | 1 | 0 | |||
| Cobenfy | 0 | ||||
| Krazati | 0 | ||||
| Inrebic | 85 | 74 | 55 | 5 | |
| Mature and other brands | 2,045 | 1,900 | 2,217 | ||
| Onureg | 124 | 73 | 17 | ||
| Empliciti | 334 | 381 | 357 | ||
| Baraclude | 555 | ||||
| Other Brands | 1,674 | ||||
| Vidaza | 58 | ||||
| Total | 45,006 | 46,159 | 46,385 | 42,518 | 26,145 |
Price Behavior
Price Behavior
| Market Price | $54.28 | |
| Market Cap ($ Bil) | 110.5 | |
| First Trading Date | 06/01/1972 | |
| Distance from 52W High | -10.7% | |
| 50 Days | 200 Days | |
| DMA Price | $48.04 | $47.93 |
| DMA Trend | down | up |
| Distance from DMA | 13.0% | 13.3% |
| 3M | 1YR | |
| Volatility | 31.5% | 29.1% |
| Downside Capture | 3.33 | 43.83 |
| Upside Capture | 99.40 | 35.98 |
| Correlation (SPY) | 12.3% | 20.8% |
BMY Betas & Captures as of 11/30/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.72 | 0.18 | 0.22 | 0.37 | 0.31 | 0.30 |
| Up Beta | 1.13 | 0.62 | 0.60 | 0.27 | 0.19 | 0.18 |
| Down Beta | -1.99 | -0.03 | -0.32 | -0.33 | 0.38 | 0.27 |
| Up Capture | 171% | 48% | 44% | 57% | 18% | 7% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 14 | 20 | 29 | 61 | 131 | 366 |
| Down Capture | 62% | -11% | 28% | 81% | 58% | 76% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 5 | 20 | 32 | 63 | 116 | 378 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of BMY With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| BMY | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 0.2% | 14.9% | 18.8% | 72.9% | 9.0% | 3.7% | -11.4% |
| Annualized Volatility | 29.0% | 17.3% | 19.5% | 19.2% | 15.3% | 17.2% | 35.0% |
| Sharpe Ratio | 0.01 | 0.64 | 0.76 | 2.72 | 0.36 | 0.05 | -0.14 |
| Correlation With Other Assets | 64.5% | 21.1% | 4.1% | -1.1% | 42.2% | 4.6% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of BMY With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| BMY | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 1.1% | 8.4% | 14.8% | 18.9% | 11.8% | 4.7% | 35.5% |
| Annualized Volatility | 23.5% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.9% |
| Sharpe Ratio | 0.02 | 0.40 | 0.70 | 0.98 | 0.51 | 0.16 | 0.62 |
| Correlation With Other Assets | 51.6% | 21.4% | 3.8% | 1.5% | 29.0% | 9.5% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of BMY With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| BMY | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 0.8% | 9.9% | 14.8% | 15.1% | 6.8% | 5.4% | 69.1% |
| Annualized Volatility | 25.1% | 16.6% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.05 | 0.49 | 0.71 | 0.85 | 0.31 | 0.23 | 0.90 |
| Correlation With Other Assets | 56.3% | 36.8% | 1.6% | 8.4% | 32.7% | 9.1% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/30/2025 | 7.1% | 9.1% | 15.4% |
| 7/31/2025 | -5.8% | -2.5% | 2.0% |
| 4/24/2025 | 0.3% | 3.4% | -3.1% |
| 2/6/2025 | -3.8% | -6.0% | 2.3% |
| 10/31/2024 | 5.9% | 5.0% | 12.5% |
| 7/26/2024 | 11.4% | 6.4% | 6.3% |
| 4/25/2024 | -8.5% | -9.5% | -15.0% |
| 2/2/2024 | 0.1% | 0.1% | 4.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 13 | 12 |
| # Negative | 12 | 11 | 12 |
| Median Positive | 2.2% | 3.5% | 3.5% |
| Median Negative | -3.4% | -2.6% | -3.2% |
| Max Positive | 11.4% | 9.1% | 15.4% |
| Max Negative | -8.5% | -9.5% | -15.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 10302025 | 10-Q 9/30/2025 |
| 6302025 | 7312025 | 10-Q 6/30/2025 |
| 3312025 | 4242025 | 10-Q 3/31/2025 |
| 12312024 | 2122025 | 10-K 12/31/2024 |
| 9302024 | 10312024 | 10-Q 9/30/2024 |
| 6302024 | 7262024 | 10-Q 6/30/2024 |
| 3312024 | 4252024 | 10-Q 3/31/2024 |
| 12312023 | 2132024 | 10-K 12/31/2023 |
| 9302023 | 10262023 | 10-Q 9/30/2023 |
| 6302023 | 7272023 | 10-Q 6/30/2023 |
| 3312023 | 4272023 | 10-Q 3/31/2023 |
| 12312022 | 2142023 | 10-K 12/31/2022 |
| 9302022 | 10262022 | 10-Q 9/30/2022 |
| 6302022 | 7272022 | 10-Q 6/30/2022 |
| 3312022 | 4292022 | 10-Q 3/31/2022 |
| 12312021 | 2092022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.